Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

Data Compilation
#PharmaFlow

Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

Stock Recap
#PipelineProspector

Gemcitabine

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

73 API Suppliers, 31 USDMF, 25 CEP/COS, 12 JDMF, 12 EU WC, 31 KDMF, 18 NDC API, 39 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

262 Drugs in Development

262 Drugs in Development

INTERMEDIATES

19 Intermediates Suppliers

19 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

245 FDF Dossiers, 88 FDA Orange Book, 89 Europe, 4 Canada, 4 Australia, 21 South Africa, 39 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 12 SPI Pharma, 1 Faran Shimi Pharmaceutical, 1 Pfanstiehl, 1 Actylis, 1 BASF, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 2 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 10 Chewable & Orodispersible Aids, 9 Taste Masking, 9 Direct Compression, 5 Parenteral, 4 Co-Processed Excipients, 3 Disintegrants & Superdisintegrants, 3 Granulation, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

4 DATA COMPILATION #PharmaFlow, 101 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 69 Finished Drug Prices, 2 Annual Reports

MARKET PLACE

16 APIs, 9 FDF Dossiers, 2 Intermediates

PATENTS & EXCLUSIVITIES

10 US Patents

10 US Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 3 Others

$ Xls download

Filters

Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

Last Updated on PharmaCompass	Virtual Booth	Country	Name of the Firm	Written Confirmation No.	Product Name	Issue Date	Valid Till	Address of the Firm
03/10/2019	Dr. Reddy's Laboratories	India	M/s. Dr. Reddy’s Laboratories Limited	WC-0039	Gemcitabine Hydrochloride	2022-06-06	2025-07-07	Unit-I, Plot Nos.137, 138, 145 & 146, Sri Venkateswara Co- Operative Industrial Estate, Bollaram (V), Jinnaram (M), Sngreddy (Dist.), Telangana State, India
27/04/2020	Dishman Carbogen Amcis	India	Dishman Carbogen Amcis Limited	WC-0135A	Gemcitabine Hydrochloride BP/USP/EP	2019-12-03	2022-07-21	Survey No. 47, Paiki Sub Plot No. 1, Village Lodariyal, Taluka Sanand, Dist. Ahmedabad- 382220, Gujarat

Gemcitabine

Gemcitabine

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

73 API Suppliers

31 USDMF

25 CEP/COS

12 JDMF

12 EU WC

31 KDMF

18 NDC API

39 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

262 Drugs in Development

INTERMEDIATES

19 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

245 FDF Dossiers

88 FDA Orange Book

89 Europe

4 Canada

4 Australia

21 South Africa

39 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

12 SPI Pharma

1 Faran Shimi Pharmaceutical

1 Pfanstiehl

1 Actylis

1 BASF

2 Gangwal Chemicals

1 Ingredion Pharma Solutions

2 Kerry

2 Microlex e.U

1 Pluviaendo

3 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders

10 Chewable & Orodispersible Aids

9 Taste Masking

9 Direct Compression

5 Parenteral

4 Co-Processed Excipients

3 Disintegrants & Superdisintegrants

3 Granulation

1 API Stability Enhancers

1 Thickeners and Stabilizers

DIGITAL CONTENT

4 DATA COMPILATION #PharmaFlow

101 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

69 Finished Drug Prices

2 Annual Reports

MARKET PLACE

16 APIs

9 FDF Dossiers

2 Intermediates

PATENTS & EXCLUSIVITIES

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons